A validated enantioselective LC-MS/MS assay for quantification of a major chiral metabolite of an achiral 11-β-hydroxysteroid-dehydrogenase 1 inhibitor in human plasma: Application to a clinical pharmacokinetic study
详细信息 查看全文
- 作者：Michael T. Furlonga ; 1 ; Qin C. Jia ; Qin.Ji@bms.com" class="auth_mail" title="E-mail the corresponding author ; Lisa Iaconob ; Oanh Dangc ; Marzena Norenc ; John Brucec ; Anne-Franç ; oise Aubrya ; Mark E. Arnolda
- 关键词：11-β-Hydroxysteroid-dehydrogenase 1 inhibitor ; Metabolite ; LC&ndash ; MS/MS ; Assay ; Chiral separation ; Pharmacokinetics
- 刊名：Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences
- 出版年：2016
- 出版时间：1 June 2016
- 年：2016
- 卷：1022
- 期：Complete
- 页码：167-172
- 全文大小：802 K
文摘
- •
BMS-823778 is a potential therapeutic agent for type 2 diabetes mellitus.
- •
BMS-823778 is metabolized in humans to a chiral metabolite by a polymorphic enzyme.
- •
An LC–MS/MS assay to quantify both metabolite enantiomers has been developed/validated.
- •
Chromatographic separation of the enantiomers was achieved by chiral chromatography.
- •
The validated LC–MS/MS assay was used to support a human pharmacokinetic study.